X4 Pharmaceuticals
XFOR
93 hedge funds and large institutions have $81.5M invested in X4 Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 28 increasing their positions, 22 reducing their positions, and 14 closing their positions.
27% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 22
21% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 14
2% more funds holding
Funds holding: 91 → 93 (+2)
0.34% less ownership
Funds ownership: 2.28% → 1.94% (-0.34%)
33% less capital invested
Capital invested by funds: $123M → $81.5M (-$41M)
54% less call options, than puts
Call options by funds: $195K | Put options by funds: $426K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
+$1.22M |
| 2 |
SCM
Sio Capital Management
New York
|
+$802K |
| 3 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$774K |
| 4 |
Morgan Stanley
New York
|
+$455K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$262K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$8.18M |
| 2 |
TLP
Tri Locum Partners
New York
|
-$6.81M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$5.75M |
| 4 |
Millennium Management
New York
|
-$1.58M |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$466K |
XFOR Hedge Fund Activity: Q4 2023 in Review
93 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q4 2023, worth a combined $81.5M — down 33% from $123M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new XFOR positions and 14 closed out — a net gain of 3 holders — while 28 added to existing stakes and 22 trimmed.
The largest buyer was Kingdon Capital Management, adding an estimated $1.22M. The largest seller was Polar Capital Holdings, exiting entirely with an estimated $8.18M sold.
- 93 institutional investors held X4 Pharmaceuticals (XFOR) as of Q4 2023, up from 91 in Q3 2023.
- Funds reported $81.5M of X4 Pharmaceuticals stock for Q4 2023, down 33% quarter-over-quarter.
- 17 funds opened new X4 Pharmaceuticals positions in Q4 2023 and 14 closed out, a net change of +3 holders.
- The largest X4 Pharmaceuticals buyer in Q4 2023 was Kingdon Capital Management, an estimated $1.22M added.
- The largest X4 Pharmaceuticals seller in Q4 2023 was Polar Capital Holdings, an estimated $8.18M sold.
Based on aggregated 13F filings for Q4 2023.